Zentiva has lost the first round of a dispute with Pfizer regarding the promotion of the cardiovascular drug Tovacard that Zentiva wants to launch in April, which is a generic version of Pfizer’s Sortis. Pfizer said that Sortis is one of its highest selling drugs (on prescription). Zentiva reportedly claimed that its drug provides the most efficient treatment, however the court ruled that both drugs contain the same active ingredients. Zentiva has to stop the promotion. Zentiva says that the launch of the drug will not be affected. Source: DNES